the existing local blood supply, which results in the tumor microenvironment becoming acidic, hypoxic, and low in nutrients. Continued malignant growth in such a compromised (ie, stressful) microenvironment requires cancer cells to initiate autophagy to parasitize the host's energy and nutrients. In the 1920s, Warburg and the Cori's demonstrated the importance of carbohydrate metabolism and lactate generation by cancers. 2, 3 Since then, a variety of potential low molecular weight nutrients, such as fatty acids, ketone bodies, and amino acids have been identified. The first indications that plasma proteins, like albumin, might be involved in tumor autophagic nutrition were reported by Mider in the late 1940's. This report concluded that tumors act as "nitrogen traps" after comparing the protein metabolism of normal tissue and of tumor tissue. 4 These studies demonstrate oneway passage of amino acids from the body pool to the tumor without any appreciable return and that even the stress of starvation does not release tumor protein for the body. In 1954, Babson and Winnick reported that cancer cells, unlike normal cells, utilized plasma proteins more efficiently than free leucine. 5 Based on these findings, they concluded that tumor growth in the starving animal and in the cachectic human is driven by the cancer cell's acquired ability to trap plasma proteins and to use the degradation products (amino acids) for proliferation, a process that normal cells do not do. Later, it was shown that albumin, in order to be utilized for its amino acid content, enters cancer cells by an active process of endocytosis. 6, 7 More recent experiments using IV injected [ exceeds the free amino acids in the plasma (ie, 2.7 mM) 117-fold. 9 Besides providing amino acids, albumin catabolism also provides a considerable source of energy, providing a rationale for why autophagic uptake and degradation of albumin is a fundamental acquired characteristic of cancer cells. 6, 7 While the half-life of albumin in the body is ∼19 days in humans, its plasma half-life is only about 1 day. 10 This is because despite tight endothelial barrier function, albumin constantly leaves the plasma via endothelial transcytosis and enters un-degraded into the extracellular fluid throughout the body. Due to this transcytosis, albumin makes ∼15 around trips from the extracellular fluid returning back to the blood via the lymphatic thoracic duct during its life-span. 10 Besides transcytosis, albumin also extravasates into the extracellular fluid within sites of metastatic cancer due to a characteristic decrease in tumor endothelial barrier function which, coupled with a lack of a functional lymphatic drainage at these sites, produces a cancer specific process known as the enhanced permeability and retention (ie, EPR) effect. 11 We have documented that due to this malignancy driven EPR effect, a small molecule therapeutic drug bound to albumin in the blood stream is concentrated appropriately sixfold within sites of prostate cancer within 24 h of dosing.
12
Coupling drugs to albumin in the blood is quite straightforward. 13 This is because albumin has a modular structural organization producing a heart-shaped molecule composed of three homologous domains, each containing an A and B subdomain. to the total thiol concentration in human plasma, which is in the range 400-500 µM. 15 Thus, the free thiol group (SH) at the Cys-34 position of HSA accounts for 80-90% of the total thiol concentration in blood plasma. 16 Importantly, the SH group of Cys-34 of HSA is the most reactive thiol group in human plasma because of the low pK a of Cys-34 in HSA, which is approximately seven compared to 8.5 and 8.9 for cysteine and glutathione, respectively 15 at physiological pH. Taken together, the SH group of Cys-34 of HSA is a unique and accessible functional group of a plasma protein that can be exploited for in situ coupling of circulating albumin following intravenous administration of a thiol-reactive prodrug. 13 The X-ray structure of the defatted protein structure reveals that cysteine-34 is located in a hydrophobic crevice on the surface of the protein that is approximately 10-12 Å deep.
14 When HSA is complexed with long-chain fatty acids as in the X-ray structure in which seven molecules of myristic acid (ie, denoted in gray circles in Figure 1 ) are bound, the crevice opens up, exposing the sulfhydryl group Cys-34. 17 This allows efficient coupling of this Cys-34 sulfhydryl to small molecular cytotoxic compounds containing a thiolreactive (eg, maleimide) group which follows second-order kinetics with second-order rate constants in the range 600-
, with the highest rate constant occurring when all of the myristic acid binding sites of albumin are saturated, as occurs in the blood. 15 Thus, the SH-group at Cys-34 of HSA is a unique and accessible functional group that can be exploited for efficient linkage of a maleimide containing cytotoxic drug derivative to albumin. 13, 15 The specific maleimide chemistry used for production of the maleimide- to >1 µM over the next 18-36 h. 23 The combination of ER stress and a sustained elevation of Ca i , eventually results in the apoptotic death of mCRPC with an LD 50 of <50 nM. 23 As part of this death response, AR protein expression is rapidly decreased in AR positive mCRPC cells. 24 In addition, 12ADT kills even multidrug resistant cells lacking apoptotic Bak and Bax proteins. 25 An additional factor is that 12ADT's potent killing ability is retained when coupled to single amino-acids.
23,24,26
2 | MATERIAL AND METHODS
| General information
All solvents and reagents used were obtained from commercial sources and used without further purification. The 
| Synthesis of 2-fluoro-5-maleimidobenzoic acid-12ADT (compound 4)
Thapsigargin was purified from Thapsia garganica seeds and 12 ADT analogue synthesized as described in detail previously. 22 Synthesis was performed as summarized in the synthetic scheme shown in Figure 3 . To obtain a stable HSA coupled 12ADT through the Cys-34 of albumin, we utilized 2-fluoro-5-maleimidobenzoic acid derivative, compound 3. This compound was synthesized as previously reported, 23, 24 but with modifications that facilitate a more efficient isolation and purification for large scale synthesis, as presented in 
| Kinetics of 2-fluoro-5-maleimidobenzoic acid-12ADT (compound 4) coupling to HSA
To determine its coupling kinetics, a mixture of 10 mM of compound 4 in phosphate buffered saline (PBS) pH 7.4 containing 100 μM solution of HSA was incubated for various time spans up to 24 h at 37°C. The mixture was then centrifuged at 18 000g for 15 min to remove any precipitate. Supernatants were then assayed using Ellman's reagent (G-Biosciences cat# BC87) according to manufacturer's instructions to determine the amount of free HSA cysteine in each solution.
Samples were read at 412 nm and free thiol concentration was determined using an extinction coefficient of 14,140 M −1 cm −1 .
| Production of 12ADT-MAD (compound 5)
A total of 10 mM solution of compound 4 was prepared in DMSO and an aliquot of this was diluted with fetal bovine serum (FBS) to 100 μM.
This was incubated at 4°C, room temperature, and 37°C to obtain the optimum reaction condition. Reactions at room temperature and 37°C were monitored over a 2 h period and the reaction at 4°C were monitored over a 24 h period. Since FBS contains ∼400 μM albumin, all compound 4 added was expected to covalently react with albumin in FBS. To determine this, at each time point 100 μL aliquot was taken and added to 300 μL of acetonitrile and the mixture was vortexed and centrifuged at 13 000 rpm for 6 min. The supernatant obtained was analyzed by analytical HPLC and MALDI-MS to determine the presence of unreacted compound 4.
| Synthesis of cysteinyl-2-fluoro-5-maleimidobenzoic acid-12ADT (compound 6)
Synthesis was performed as summarized in the synthetic scheme shown in Figure 4 . To obtain compound 6, 30 mg (0.0301 mmol) of compound 4 was dissolved in 3.5 mL DMF and to this was added 
| Cell lines and cell culture assays
The culture conditions and media for all of the human prostate cancer lines used in these studies (ie, LNCaP, LAPC-4, VCaP, CWR22Rv1, PC-3, DU-145) are as described previously. 23, 24 All lines were mycoplasma negative using the MycoSensor PCR Assay kit (Agilent Technologies, La Jolla, CA) and genetically authenticated within the last 6 months using STR profiling performed by the Johns Hopkins Genetic Resource Core Facility. Cell viability at various times post exposure to test compounds was determined using trypan blue exclusion as previously described. 23 The dose-response ability of test compounds to kill prostate cancer cells was determined using a clonogenic survival assay as described previously, 23 with the results expressed as the nmol/L concentration needed to lose 50% of the clonogenic ability (ie, LD 50 ) after 48 h of exposure to the test compound. In addition, MTT growth assays performed as described previously 27 were used to confirm the clonogenic results. SERCA pump inhibition, expressed as the concentration needed to inhibit 50% of the enzymatic activities (IC 50 value) and the change in the intracellular Ca +2 concentration were determined as previously described. These data document that when Cys-34 in albumin is "capped,"
the protein is "recognized" differently than unmodified albumin and is phagocytized and degraded into its free amino-acids by cancer cells.
Thus by capping albumin with a 2-fluoro-5-maleimidobenzoic acid 
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